Advice
Following a full submission
tenofovir (Viread®) is accepted for use within NHS Scotland for the treatment of chronic hepatitis B in adults with compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.
Tenofovir has been shown to be significantly more effective than another nucleoside reverse transcriptase inhibitor in achieving a complete composite response (virological plus histological response) in a greater proportion of patients with chronic hepatitis B infection with HBeAg positive and HBeAg negative disease.
Download detailed advice95KB (PDF)
Medicine details
- Medicine name:
- tenofovir (Viread)
- SMC ID:
- 479/08
- Indication:
- chronic hepatitis B (CHB) in adults with compensated liver disease with evidence of active viral replication, persistently (i.e. at least 6 months) elevated serum alanine aminotra
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 July 2008